- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-1/A IPO registration
- 3.1 EX-3.1
- 3.2 EX-3.2
- 5.1 EX-5.1
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 23.2 EX-23.2
- 23.3 EX-23.3
- EX-FILING FEES Calculation of Filing Fee Table
- 15 Aug 24 EFFECT Notice of effectiveness
- 13 Aug 24 POS AM Prospectus update (post-effective amendment)
- 30 Jan 24 424B4 Prospectus supplement with pricing info
- 25 Jan 24 EFFECT Notice of effectiveness
- 24 Jan 24 S-1/A IPO registration (amended)
- 24 Jan 24 S-1/A IPO registration (amended)
- 22 Jan 24 S-1/A IPO registration (amended)
- 12 Jan 24 S-1/A IPO registration (amended)
- 14 Dec 23 FWP Free writing prospectus
- 7 Dec 23 S-1/A IPO registration (amended)
- 4 Dec 23 S-1/A IPO registration (amended)
- 30 Nov 23 S-1/A IPO registration (amended)
-
27 Nov 23 S-1/A IPO registration (amended)
- 7 Nov 23 S-1 IPO registration
Exhibit 23.3
June 24, 2023
Summary of animal study results from Howard An, M.D., Director, Spine Fellowship Program, Rush University Medical College:
Our studies have shown that this biological treatment using human dermal fibroblast cells, has great potential as a cell therapy for disc degeneration. When these cells were injected into a degenerating rabbit disc, they were retained in the disc for up to 8 weeks. Collagen Type II gene expression, a marker for disc repair and regeneration, was higher in the discs treated with human dermal fibroblast cells than those in the control treatment. Also higher in the cell treated discs were the disc heights and cell number. Together, this data suggests that human dermal fibroblast cells are a promising option for cell therapy to restore the biological function and reduce symptoms of intermediate or progressive degenerative discs.
I approve for Fibrobiologics Inc. to use this statement for S-1 filing.
 | |
| Howard S. An, M.D |